mitogen-activated protein kinase 7 isoform 1 phosphorylated 1 (human)

A mitogen-activated protein kinase 7 isoform 1 phosphorylated 1 in human. UniProtKB:Q13164-1, Thr-28/Thr-219/Thr-733, MOD:00047|Tyr-221, MOD:00048|Ser-421/Ser-433/Ser-496/Ser-731, MOD:00046.


mitogen-activated protein kinase 7 isoform h4 (human)

A mitogen-activated protein kinase 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q13164-4.


mitogen-activated protein kinase 7 isoform 1 (human)

A mitogen-activated protein kinase 7 isoform 1 that is encoded in the genome of human.


osteogenesis imperfecta type 12

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

Any osteogenesis imperfecta in which the cause of the disease is a mutation in the SP7 gene.


combined immunodeficiency due to DOCK8 deficiency

Combined immunodeficiency due to dedicator of cytokinesis 8 protein (DOCK8) deficiency is a form of T and B cell immunodeficiency characterized by recurrent cutaneous viral infections, susceptibility to cancer and elevated serum levels of immunoglobulin E (IgE).


heat shock protein HSP 90-alpha isoform 1 (human)

A heat shock protein HSP 90-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P07900-1.


cftr isoform 1 phosphorylated 2 (human)

A cftr isoform 1 phosphorylated 2 in human. Example: UniProtKB:P13569-1, Ser-686/Ser-737/Ser-768/Ser-790/Ser-795/Ser-813, MOD:00046.


cytochrome P450 3A7 isoform h1 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-1.


cytochrome P450 3A7 isoform h2 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-2.


Acrodysostosis 1 with or without hormone resistance

An autosomal dominant skeletal dysplasia caused by mutation(s) in the PRKAR1A gene, encoding cAMP-dependent protein kinase type I-alpha regulatory subunit. It is characterized by short stature, brachydactyly, and characteristic facial features. Resistance to multiple hormones is a common finding.


acrodysostosis

Acrodysostosis (ACRDYS) is a rare primary bone dysplasia characterized by severe brachydactyly, peripheral dysostosis with facial dysostosis, nasal hypoplasia, and developmental delay.


acrodysostosis 2 with or without hormone resistance

Any acrodysostosis in which the cause of the disease is a mutation in the PDE4D gene.


DNA polymerase delta catalytic subunit phosphorylated 1 (human)

A DNA polymerase delta catalytic subunit (human) that has been phosphorylated on the residue at the position equivalent to Ser-928 of the amino acid sequence represented by UniProtKB:P28340. UniProtKB:P28340, Ser-928, MOD:00046.


ethmoidal sinus neoplasm

A benign or malignant neoplasm that affects the ethmoid sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of sphenoidal sinus

A non-metastasizing neoplasm that arises from the sphenoid sinus.


sphenoidal sinus neoplasm

A benign or malignant neoplasm that affects the sphenoid sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


maxillary sinus neoplasm

A benign or malignant neoplasm that affects the maxillary sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of ethmoidal sinus

A benign neoplasm that involves the ethmoid sinus.


benign neoplasm of maxillary sinus

A benign neoplasm that involves the maxillary sinus.


paranasal sinus cancer

A primary or metastatic malignant neoplasm involving the paranasal sinuses.


ethmoid sinus ectopic meningioma

An extremely rare meningioma that arises as a primary ectopic tumor in the ethmoid sinus.


frontal sinus neoplasm

A benign or malignant neoplasm that affects the frontal sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of frontal sinus

A benign neoplasm that involves the frontal sinus.


paranasal sinus lymphoma

A lymphoma that arises from the paranasal sinus. Representative examples include diffuse large B-cell lymphoma and extranodal NK/T-cell lymphoma, nasal type.


induced myeloid leukemia cell differentiation protein Mcl-1 isoform h1 (human)

An induced myeloid leukemia cell differentiation protein Mcl-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q07820-1.


histone deacetylase 1 isoform 1 (rat)

A histone deacetylase 1 isoform 1 that is encoded in the genome of rat.


histone deacetylase 1 isoform 1 (human)

A histone deacetylase 1 isoform 1 that is encoded in the genome of human.


histone deacetylase 1 isoform 1 (mouse)

A histone deacetylase 1 isoform 1 that is encoded in the genome of mouse.


Carcinoid tumor of the duodenum

A well differentiated, low grade neuroendocrine neoplasm (carcinoid tumor) that arises from the duodenum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.


activated factor Xa heavy chain (human)

An activated factor Xa heavy chain in human. UniProtKB:P00742, 235-488.


Grade 3 Chylothorax, CTCAE

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

Severe symptoms; elective operative intervention indicated


adult germ cell tumor

A germ cell tumor that occurs during adulthood.


adult teratoma

A teratoma that occurs in an adult.


adult cystic teratoma

A cystic teratoma that occurs in an adult.


amyotrophic lateral sclerosis type 11

Any amyotrophic lateral sclerosis in which the cause of the disease is a mutation in the FIG4 gene.


thymidine phosphorylase isoform h2 (human)

A thymidine phosphorylase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P19971-2.


serine/threonine-protein kinase N3 phosphorylated 1 (human)

A serine/threonine-protein kinase N3 (human) that has been phosphorylated on the residue at the position equivalent to Thr-718 of the amino acid sequence represented by UniProtKB:Q6P5Z2. UniProtKB:Q6P5Z2, Thr-718, MOD:00047.


facioscapulohumeral muscular dystrophy 1

Any facioscapulohumeral muscular dystrophy in which the cause of the disease is a mutation in the FRG1 gene.


Gollop-Wolfgang complex

Gollop-Wolfgang complex is a very rare malformation characterized by ectrodactyly of the hand and ipsilateral bifurcation of the femur.


Metastatic Salivary Duct Carcinoma

Salivary duct carcinoma that has spread from its original site of growth to another anatomic site.


Recurrent Salivary Duct Carcinoma

The reemergence of salivary duct carcinoma after a period of remission.


tissue-type plasminogen activator N-glycosylated 16 (human)

A tissue-type plasminogen activator (human) that has been N-glycosylated at the residue equivalent to Asn-152 of the amino acid sequence represented by UniProtKB:P00750-1, in which the glycan structure is represented by GlyTouCan:G77038WW. Example: UniProtKB:P00750-1, Asn-152, MOD:00160~GNO:G77038WW.


Stage I Rectal Neuroendocrine Tumor AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


acetylcholine receptor subunit delta isoform 1 (human)

An acetylcholine receptor subunit delta isoform 1 that is encoded in the genome of human.


acetylcholine receptor subunit delta, signal peptide removed form (human)

An acetylcholine receptor subunit delta (human) that has had the signal peptide removed. UniProtKB:Q07001, 22-517.


acetylcholine receptor subunit delta isoform h2 (human)

An acetylcholine receptor subunit delta (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q07001-2.


isoleucine--tRNA ligase, cytoplasmic methylated 1 (human)

An isoleucine--tRNA ligase, cytoplasmic (human) that has been methylated on the residue at the position equivalent to Cys-336 of the amino acid sequence represented by UniProtKB:P41252. UniProtKB:P41252, Cys-336, MOD:00660.


CIC-DUX4 Sarcoma

An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and DUX4 gene on chromosome 4. The translocation results in CIC-DUX4, t(4;19)(q35;q13) fusions.


mast/stem cell growth factor receptor Kit sequence variant V560G, signal peptide removed form (human)

A mast/stem cell growth factor receptor Kit (human) that has a Gly residue at the position equivalent to Val-560 of the amino acid sequence represented by UniProtKB:P10721-1 and that has had the signal peptide removed. Example: UniProtKB:P10721-1, 26-976, Val-560, CHEBI:29947.


Cacosmia

A hallucination of an unpleasant odor.


aminodiol

An amino alcohol having two hydroxy functional groups.


corrinoid adenosyltransferase MMAB sequence variant R186W, transit peptide removed form (human)

A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-186 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-186, CHEBI:29954.


corrinoid adenosyltransferase MMAB

A protein that is a translation product of the human MMAB gene or a 1:1 ortholog thereof.


corrinoid adenosyltransferase MMAB sequence variant R191W, transit peptide removed form (human)

A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-191 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-191, CHEBI:29954.


corrinoid adenosyltransferase MMAB sequence variant E193L, transit peptide removed form (human)

A corrinoid adenosyltransferase MMAB (human) that has a Leu residue at the position equivalent to Glu-193 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Glu-193, CHEBI:30006.


corrinoid adenosyltransferase MMAB, transit peptide removed form (human)

A corrinoid adenosyltransferase MMAB (human) that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250.


5-hydroxytryptamine receptor 2A isoform h2 (human)

A 5-hydroxytryptamine receptor 2A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P28223-2.


chronic lymphocytic leukemia/small lymphocytic lymphoma

An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.


intrapelvic lymph node leukemic reticuloendotheliosis


refractory hairy cell leukemia

Hairy cell leukemia that is resistant to treatment.


pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.


chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.


hairy cell leukemia variant

Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).


pars planitis

An inflammatory disorder of the cilliary body in the uvea that affects healthy, younger individuals who are often asymptomatic. It has a long clinical course with relapses and remissions. Symptoms include mildly decreased vision and floaters. It may be associated with autoimmune disorders.


transcriptional enhancer factor TEF-5, initiator methionine removed form (human)

A transcriptional enhancer factor TEF-5 (human) that has had the initiator methionine removed. UniProtKB:Q99594, 2-435.


Breast Classic Lobular Carcinoma In Situ Type B

Breast classic lobular carcinoma in situ  characterized by the presence of neoplastic cells with nuclei of various sizes and shapes.


Early Stage HER2-Negative Breast Carcinoma

HER2-negative breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Prognostic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


Intraductal Micropapillary Breast Carcinoma

Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


Solid papillary carcinoma in situ of breast

Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Recurrent Hormone Receptor-Negative Breast Carcinoma

The reemergence of hormone receptor-negative breast carcinoma after a period of remission.


breast angiosarcoma

A malignant vascular neoplasm arising from the breast.


Invasive Breast Lobular Carcinoma, Solid Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


Metastatic Triple-Negative Breast Carcinoma

A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Invasive Breast Lobular Carcinoma with Predominant In Situ Component

A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

The reemergence of a malignant breast neoplasm after a period of remission.


Invasive Breast Lobular Carcinoma, Alveolar Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


High Grade Ductal Breast Carcinoma In Situ

Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


Breast Carcinoma Metastatic in the Liver

A carcinoma that originates from the breast and has spread to the liver.


Unresectable HER2-Negative Breast Carcinoma

HER2-negative breast carcinoma that is not amenable to surgical resection.


Histiocytoid Breast Carcinoma

A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


Squamous Cell Carcinoma In Situ of the Nipple

An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Prognostic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Locally Recurrent Breast Carcinoma

The reemergence of breast carcinoma after a period of remission, at or adjacent to the site of the original tumor.


Refractory HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that is resistant to treatment.


Invasive Breast Solid Papillary Carcinoma

Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


adenocarcinoma of breast with neuroendocrine differentiation

An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


Metastatic Breast Inflammatory Carcinoma

Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


Metastatic Breast Neuroendocrine Tumor G1

A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


Unresectable Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that is not amenable to surgical resection.


Breast Classic Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


Refractory Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that is resistant to treatment.


Breast Periductal Stromal Tumor

A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


Metastatic HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread to another anatomic site.


Recurrent HER2-Positive Breast Carcinoma

The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


Hormone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for hormone receptors.


Refractory Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


breast leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the breast. It is characterized by a proliferation of neoplastic spindle cells.


Malignant nipple neoplasm male

A malignant neoplasm that affects the area of the nipple in males.


Metastatic Breast Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


Inflammatory carcinoma of breast stage III

Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


High Grade Breast Mucoepidermoid Carcinoma

An aggressive mucoepidermoid carcinoma characterized by the presence of focal necrosis and high mitotic activity.  Lymph node and distant metastases are common.  The prognosis is usually poor.


Postradiation Breast Angiosarcoma

A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


Progesterone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for progesterone receptors.


Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


Metastatic Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Multicentric Breast Carcinoma

A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


Breast Cancer by AJCC v8 Prognostic Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Locally Advanced HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Prognostic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Low Grade Breast Adenosquamous Carcinoma

A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


Refractory Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that is resistant to treatment.


Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

Breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


Metastatic Breast Signet Ring Cell Carcinoma

A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


Recurrent Estrogen Receptor-Positive Breast Carcinoma

The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Inflammatory carcinoma of breast recurrent

The reemergence of inflammatory carcinoma of the breast after a period of remission


Breast Carcinoma with Choriocarcinomatous Features

An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


Prognostic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


Intraductal papillary adenocarcinoma with invasion

A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

The reemergence of breast angiosarcoma after a period of remission.


Anatomic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Malignant neoplasm of nipple of female breast

A malignant neoplasm that affects the area of the nipple in females.


Paget's disease and infiltrating duct carcinoma of breast

Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Breast Lobular Carcinoma, Tubulolobular Variant

An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


Hormone Receptor-Negative Breast Carcinoma

Breast adenocarcinoma that is negative for hormone receptors.


Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

The reemergence of breast sarcoma after a period of remission.


Breast Carcinoma with Osseous Metaplasia

An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Unresectable Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


Prognostic Stage IA Breast Cancer AJCC v8

Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Pleomorphic lobular carcinoma in situ of breast

Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


Invasive micropapillary carcinoma of breast

An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


Anatomic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


Paget's disease and intraductal carcinoma of breast

Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

Breast adenocarcinoma that does not respond to treatment.


Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

Breast carcinoma that is not amenable to surgical resection.


Recurrent HER2-Negative Breast Carcinoma

The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

The reemergence of breast adenocarcinoma after a period of remission.


PALB2-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


Recurrent Invasive Breast Carcinoma of No Special Type

The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

Breast lymphoma that is resistant to treatment.


Malignant nipple neoplasm

A malignant neoplasm that affects the area of the nipple.


Breast Ductal Carcinoma In Situ, Comedo Type

Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


Prognostic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


solid type ductal carcinoma in situ of breast

Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


breast liposarcoma

A malignant adipose tissue neoplasm of the breast.


Prognostic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Metastatic Androgen Receptor-Positive Breast Carcinoma

Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


breast sarcoma

A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


Anatomic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Prognostic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Triple-Negative Breast Inflammatory Carcinoma

Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Breast Tall Cell Carcinoma with Reversed Polarity

A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


Androgen Receptor-Positive Breast Carcinoma

Breast carcinoma that is positive for androgen receptors.


Synchronous Ipsilateral Breast Carcinoma

Diagnosis of more than one distinct tumor focus in the same breast, within two months.


Anatomic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

A well differentiated invasive breast carcinoma.


Unresectable HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that is not amenable to surgical resection.


Grade 3 Invasive Breast Carcinoma

A poorly differentiated invasive breast carcinoma.


Unresectable Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.


Stage IB Breast Cancer AJCC v7

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Breast Cancer by AJCC v7 Stage

A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Ductal Carcinoma In Situ and Lobular Carcinoma

A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


breast extraskeletal osteosarcoma

An osteosarcoma arising from the breast tissue.


Breast Ductal Carcinoma In Situ, Non-Comedo Type

Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


Locally Advanced Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Invasive Breast Lobular Carcinoma, Signet Ring Variant

An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


Prognostic Stage I Breast Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Breast Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the breast parenchyma and has metastasized to other anatomic sites.


Invasive papillary breast carcinoma

An invasive breast carcinoma characterized by the presence of papillary structures.


adenocarcinoma of breast with spindle cell metaplasia

An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.


Recurrent Progesterone Receptor-Positive Breast Carcinoma

The reemergence of progesterone receptor-positive breast carcinoma after a period of remission.


Metastatic Breast Carcinoma in the Skin

A carcinoma that arises from the breast and has metastasized to the skin.


Anatomic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Ductal Carcinoma In Situ with Microinvasion

Invasive breast carcinoma measuring 1 mm or less in size.


Early Stage Breast Carcinoma

Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Unresectable Breast Inflammatory Carcinoma

Inflammatory breast carcinoma that is not amenable to surgical resection.


Invasive Female Breast Carcinoma

An invasive carcinoma that arises from the breast in females.


Refractory HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that is resistant to treatment.


Breast Carcinoma with Chondroid Metaplasia

An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.


Metastatic HER2-Low Breast Carcinoma

HER2-low breast adenocarcinoma that has spread from its original site of growth to another anatomic site.


malignant breast phyllodes tumor

A phyllodes tumor of the breast characterized by infiltrative margins and a sarcomatous stromal component. The sarcomatous stroma usually displays features of fibrosarcoma. Liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous elements may also be present.


Hereditary Male Breast Carcinoma

Breast carcinoma that has developed in male relatives of patients with history of breast carcinoma.


Recurrent Breast Paget Disease

The reemergence of Paget disease of the breast after a period of remission.


Early Stage Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that has not spread beyond the breast or axillary lymph nodes.


Locally Advanced Breast Adenocarcinoma

Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Breast Carcinoma

A rare breast carcinoma that occurs during childhood.


Breast Ductal Carcinoma with Squamous Metaplasia

An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the ductal carcinomatous component.


Metastatic Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Stage IA Breast Cancer AJCC v7

Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast lymphoma

A lymphoma that arises from the breast. There is no history of extramammary breast lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast lymphoma. Most patients present with a painless breast lump. The vast majority of cases are B-cell non-Hodgkin lymphomas. Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast. Primary Hodgkin lymphoma of the breast is rare.


Invasive Breast Lobular Carcinoma, Pleomorphic Variant

A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.


Breast Cancer by AJCC v8 Anatomic Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)


Breast Mixed Carcinoma

An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.


Breast Carcinoma with Melanotic Features

A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.


Breast Paget Disease without Invasive Carcinoma

Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.


Refractory Breast Carcinoma

Breast carcinoma that does not respond to treatment.


Breast Cancer by AJCC v8 Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)


Breast Classic Lobular Carcinoma In Situ Type A

Breast classic lobular carcinoma in situ characterized by the presence of neoplastic cells with uniform nuclei.


Unresectable Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Inflammatory carcinoma of breast stage IV

An inflammatory carcinoma of the breast that has spread to other anatomic sites.


Metastatic HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that has spread from the original site of growth to another anatomic site.


Prognostic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Cancer by AJCC v6 Stage

A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 6th edition.


Recurrent Breast Lymphoma

The reemergence of breast lymphoma after a period of remission.


Breast Ductal Carcinoma In Situ, Low Grade

Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.


Locally Advanced Breast Carcinoma

A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Contralateral Breast Carcinoma

Breast carcinoma that develops in the opposite breast of a patient with an already diagnosed primary breast carcinoma.


Prognostic Stage IB Breast Cancer AJCC v8

Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Squamous Cell Carcinoma in the Breast

A squamous cell carcinoma that has spread to the breast from another anatomic site.


malignant breast melanoma

A melanoma that arises usually from the breast skin and less often from the breast glandular tissue. Primary breast melanomas are rare.


Prognostic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Oligometastatic Breast Carcinoma

Breast carcinoma that has metastasized to a limited number of sites.


Encapsulated Breast Papillary Carcinoma

Breast carcinoma characterized by the presence of fine fibrovascular stalks covered by neoplastic epithelial cells of low or intermediate nuclear grade, typically present within a cystic space and surrounded by a fibrous capsule. There are usually no myoepithelial cells along the papillae or at the periphery of the lesion. (WHO 2019)


Breast Carcinoma Metastatic in the Brain

A carcinoma that has spread to the brain from its original site in the breast, through the hematogenous route.


Encapsulated Breast Papillary Carcinoma with Invasion

Encapsulated breast papillary carcinoma characterized by the presence of neoplastic elements that permeate beyond the fibrous capsule with an irregular infiltrative appearance. (WHO 2019)


Breast Carcinoma with Osteoclast-Like Stromal Giant Cells

An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.


Grade 2 Invasive Breast Carcinoma

A moderately differentiated invasive breast carcinoma.


Anatomic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Malignant Breast Neoplasm

A malignant breast neoplasm that has metastasized to another anatomic site.


Resectable Breast Carcinoma

Breast carcinoma that is amenable to surgical resection.


Low Grade Breast Mucoepidermoid Carcinoma

A slow growing mucoepidermoid carcinoma characterized by the presence of keratinization in the neoplastic squamous cells and lumina formation by glandular neoplastic cells.  Complete excision may be curative.


Metastatic BRCA-Associated Breast Carcinoma

BRCA-associated breast carcinoma that has spread to another anatomic site.


Recurrent Lobular Breast Carcinoma

The reemergence of lobular breast carcinoma after a period of remission.


Estrogen Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for estrogen receptors.


Invasive Breast Lobular Carcinoma with Extracellular Mucin

A rare variant of invasive breast lobular carcinoma characterized by the presence of pools of extracellular mucin in which groups of floating lobular carcinoma cells are identified.


Breast Ductal Carcinoma In Situ, Intermediate Grade

Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.


Recurrent Hormone Receptor-Positive Breast Carcinoma

The reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.


adenocarcinoma of breast with squamous metaplasia

An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the adenocarcinoma component.


Recurrent Triple-Negative Breast Carcinoma

The reemergence of triple-negative breast carcinoma after a period of remission.


Metastatic Progesterone Receptor-Positive Breast Carcinoma

Progesterone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Neuroendocrine Carcinoma

A neuroendocrine carcinoma arising from the breast. It is classified as small cell or large cell neuroendocrine carcinoma.


Locally Advanced HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Breast Ductal Carcinoma

A ductal breast carcinoma that has spread from the original site of growth to another anatomic site.